Three Motley Fool contributors believe they have found some great dividend stocks that fit the bill. Here's why they think ...

Offsetting Humira's expected declines ... Since being divested from Abbott, AbbVie has largely focused on a dividend payout ratio close to 50%, which seems appropriate, given the maturity of ...

A high yield can be attractive, but the most critical factor to consider is a company's underlying operations. Here are two ...

When AbbVie spun off from Abbott in 2013, the writing was already on the wall for its autoimmune disease drug Humira losing exclusivity. Not only did Humira rank as AbbVie's top-selling product ...

Humira's sales peaked at $21.2 billion ... When counting the time it spent under Abbott Laboratories, AbbVie has increased its payouts for 53 consecutive years. It's not like the drugmaker ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Winter founded Cambridge Antibody Technology in 1989, which first discovered adalimumab using phage display technology as part of a development partnership with BASF Pharma. After Abbott bought ...

The fully human anti-TNF-α antibody adalimumab (Humira; Abbott) was approved by the FDA in 2007. This year, it has been joined by natalizumab (Tysabri; Elan/Biogen-Idec), a humanized antibody ...

Abbott Laboratories is a dividend stock you ... stronger after losing patent exclusivity for its blockbuster drug Humira. Johnson & Johnson is a seasoned dividend payer for all seasons.

Abbott Laboratories has been paying a dividend ... a matter of time before key patents for its autoimmune disease drug Humira would expire. The company was heavily dependent on Humira's sales.